In a landmark achievement for West Africa’s biotechnology sector, Revna Biosciences (RevnaBio) has secured a rare "triple accreditation" from the American Association for Laboratory Accreditation (A2LA). This global recognition validates RevnaBio’s systems across clinical diagnostics, biobanking, and proficiency testing, effectively removing the need
for Ghanaian clinicians to send advanced genetic samples overseas.
By meeting these three distinct international standards simultaneously, RevnaBio is positioning Accra as a primary node in the global network of precision medicine and pharmaceutical research.
1. The "Triple Crown" of Laboratory Standards
The accreditation covers three critical ISO standards that govern the entire lifecycle of a medical sample—from the patient’s arm to the researcher’s data set.
The RevnaBio Accreditation Portfolio: | ISO Standard | Focus Area | Impact on Ghana Healthcare | | :--- | :--- | :--- | | ISO 15189 | Medical Laboratories | Guarantees world-class accuracy and traceability for molecular and genomic clinical testing. | | ISO 20387 | Biobanking | Validates the ethical and scientific storage of African biospecimens for global research. | | ISO/IEC 17043 | Proficiency Testing | Authorizes RevnaBio to grade and improve the performance of other labs in the region. |
2. Ending "Diagnostic Flight"
Derrick Akpalu, CEO and co-founder of RevnaBio, emphasized that this milestone is a "Infrastructure Reset" for the region. Traditionally, complex molecular tests for cancer or rare genetic disorders required shipping samples to Europe or the U.S., leading to delays and high costs.
-
Local Accuracy: Clinicians in Ghana can now access internationally validated genomic testing locally.
-
Global Collaboration: The accreditation makes RevnaBio a "plug-and-play" partner for global pharmaceutical firms and research institutions looking to include African genetic diversity in their clinical trials.
3. Biobanking: Protecting Africa’s Genetic Heritage
With the ISO 20387 accreditation, RevnaBio is now a certified custodian of African biological data. This is critical for "Genomic Sovereignty," ensuring that research involving African populations is conducted with the highest ethical oversight.
-
Research-Grade Specimens: The facility can collect, process, and store specimens that meet the rigorous requirements of international drug developers.
-
Diverse Datasets: RevnaBio’s infrastructure in Accra specifically aims to generate clinical datasets that reflect the unique genetic diversity of the African continent.
4. Scientific Excellence and Board Vision
Ms. Jennifer Dent, a RevnaBio Board member, noted that the triple accreditation is a testament to the team's commitment to "scientific excellence." Founded in 2017 and domiciled in the U.S., RevnaBio’s decision to build its core infrastructure in Accra represents a long-term bet on Ghana’s potential as a biotech leader.
The Bottom Line
The A2LA triple accreditation is a "Biotech Reset" for West Africa. By becoming a certified proficiency testing provider (ISO 17043), RevnaBio isn't just a participant in the market; it is now a regulator of quality for the entire regional laboratory ecosystem. For the Ghanaian patient, this means faster, more accurate, and more personalized medical care right at home.
